Entero Therapeutics, Inc. (NASDAQ:GRDX) Shares Shorted: Short Interest Up 91.8% in September

Entero Therapeutics, Inc. (NASDAQ:GRDX) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totaling 104,553 shares, a growth of 91.8% from the September 15th total of 54,523 shares. Based on an average daily volume of 74,913 shares, the days-to-cover ratio is currently 1.4 days. Approximately 1.5% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Separately, Wall Street Zen lowered shares of Entero Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 29th.

Entero Therapeutics Stock Up 4.9%

Shares of NASDAQ:GRDX traded up $0.21 during midday trading on Thursday, reaching $4.46. The company had a trading volume of 161,316 shares, compared to its average volume of 115,853. Entero Therapeutics has a 1-year low of $1.87 and a 1-year high of $6.93. The stock has a market cap of $31.80 million, a PE ratio of -2.35 and a beta of 1.69. The business’s 50 day moving average price is $3.61 and its 200 day moving average price is $3.70.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for gastrointestinal disorders. The company’s work is centered on treatments intended to address unmet needs in conditions involving inflammation, immune responses and intestinal health.

Its lead development program is latiglutenase, an oral enzyme therapy designed to break down immunogenic gluten fragments in the digestive tract. The program is being developed for celiac disease, an autoimmune disorder triggered by gluten exposure.